News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
389,409 Results
Type
Article (25401)
Company Profile (32)
Press Release (363973)
Multimedia
Podcasts (125)
Webinars (16)
Section
Business (122813)
Career Advice (1474)
Deals (17899)
Drug Delivery (80)
Drug Development (43985)
Employer Resources (101)
FDA (9055)
Job Trends (8801)
News (196292)
Policy (17807)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1507)
Academic (1)
Accelerated approval (18)
Adcomms (15)
Allergies (93)
Alliances (33918)
ALS (110)
Alzheimer's disease (1028)
Antibody-drug conjugate (ADC) (229)
Approvals (9299)
Artificial intelligence (364)
Autoimmune disease (109)
Automation (30)
Bankruptcy (163)
Best Places to Work (7251)
BIOSECURE Act (12)
Biosimilars (118)
Biotechnology (26)
Bladder cancer (122)
Brain cancer (38)
Breast cancer (439)
Cancer (3401)
Cardiovascular disease (289)
Career advice (1270)
Career pathing (31)
CAR-T (150)
CDC (33)
Cell therapy (480)
Cervical cancer (27)
Clinical research (38036)
Collaboration (1352)
Company closure (2)
Compensation (296)
Complete response letters (30)
COVID-19 (1604)
CRISPR (66)
C-suite (492)
Cystic fibrosis (85)
Data (4446)
Decentralized trials (2)
Denatured (41)
Depression (85)
Diabetes (345)
Diagnostics (3683)
Digital health (29)
Diversity (7)
Diversity, equity & inclusion (31)
Drug discovery (182)
Drug pricing (125)
Drug shortages (21)
Duchenne muscular dystrophy (153)
Earnings (58741)
Editorial (46)
Employer branding (14)
Employer resources (89)
Events (58507)
Executive appointments (578)
FDA (11156)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (6)
Frontotemporal dementia (17)
Funding (869)
Gene editing (134)
Generative AI (41)
Gene therapy (416)
GLP-1 (624)
Government (2569)
Grass and pollen (6)
Guidances (325)
Healthcare (10472)
HIV (49)
Huntington's disease (30)
IgA nephropathy (60)
Immunology and inflammation (159)
Immuno-oncology (49)
Indications (95)
Infectious disease (1769)
Inflammatory bowel disease (134)
Inflation Reduction Act (14)
Influenza (66)
Intellectual property (162)
Interviews (274)
IPO (8544)
IRA (37)
Job creations (1869)
Job search strategy (1030)
JPM (45)
Kidney cancer (13)
Labor market (55)
Layoffs (303)
Leadership (31)
Legal (4570)
Liver cancer (50)
Longevity (10)
Lung cancer (487)
Lymphoma (277)
Machine learning (24)
Management (34)
Manufacturing (539)
MASH (125)
Medical device (6902)
Medtech (6937)
Mergers & acquisitions (10066)
Metabolic disorders (855)
Multiple sclerosis (121)
NASH (9)
Neurodegenerative disease (203)
Neuropsychiatric disorders (54)
Neuroscience (1819)
NextGen: Class of 2026 (3561)
Non-profit (2760)
Now hiring (9)
Obesity (375)
Opinion (217)
Ovarian cancer (98)
Pain (124)
Pancreatic cancer (145)
Parkinson's disease (172)
Partnered (21)
Patents (301)
Patient recruitment (260)
Peanut (30)
People (30053)
Pharmaceutical (10)
Pharmacy benefit managers (17)
Phase 1 (11422)
Phase 2 (16224)
Phase 3 (13639)
Pipeline (4175)
Policy (201)
Postmarket research (1694)
Preclinical (4923)
Press Release (31)
Prostate cancer (208)
Psychedelics (31)
Radiopharmaceuticals (178)
Rare diseases (563)
Real estate (2724)
Recruiting (39)
Regulatory (13455)
Reports (26)
Research institute (1411)
Resumes & cover letters (223)
Rett syndrome (19)
RNA editing (10)
RSV (53)
Schizophrenia (98)
Series A (152)
Series B (100)
Service/supplier (3)
Sickle cell disease (69)
Special edition (15)
Spinal muscular atrophy (77)
Sponsored (27)
Startups (1630)
State (1)
Stomach cancer (15)
Supply chain (63)
Tariffs (54)
The Weekly (81)
Vaccines (682)
Venture capital (55)
Weight loss (234)
Women's health (58)
Worklife (16)
Date
Today (122)
Last 7 days (470)
Last 30 days (1541)
Last 365 days (19316)
2026 (2711)
2025 (19407)
2024 (20723)
2023 (22822)
2022 (29379)
2021 (31154)
2020 (30344)
2019 (26026)
2018 (19252)
2017 (18129)
2016 (17561)
2015 (19990)
2014 (16644)
2013 (14560)
2012 (14454)
2011 (13922)
2010 (13116)
Location
Africa (575)
Alabama (62)
Alaska (6)
Arizona (132)
Arkansas (7)
Asia (22660)
Australia (3819)
California (6787)
Canada (2036)
China (718)
Colorado (317)
Connecticut (342)
Delaware (216)
Europe (53891)
Florida (1140)
Georgia (231)
Hawaii (1)
Idaho (23)
Illinois (504)
India (50)
Indiana (373)
Iowa (10)
Japan (320)
Kansas (74)
Kentucky (18)
Louisiana (8)
Maine (32)
Maryland (849)
Massachusetts (5005)
Michigan (205)
Minnesota (302)
Mississippi (2)
Missouri (59)
Montana (11)
Nebraska (9)
Nevada (79)
New Hampshire (36)
New Jersey (2204)
New Mexico (13)
New York (1947)
North Carolina (916)
North Dakota (5)
Northern California (3274)
Ohio (177)
Oklahoma (14)
Oregon (21)
Pennsylvania (1468)
Puerto Rico (25)
Rhode Island (31)
South America (853)
South Carolina (32)
Southern California (2755)
Tennessee (125)
Texas (1055)
United States (24978)
Utah (225)
Vermont (1)
Virginia (162)
Washington D.C. (56)
Washington State (560)
West Virginia (3)
Wisconsin (65)
Wyoming (2)
389,409 Results for "merck sharp and dohmen arecibo puerto rico".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
February 3, 2026
·
4 min read
·
Nick Paul Taylor
Manufacturing
PharmaEssentia Shores Up Supply With $46M Investment in Puerto Rico Plant
The Taiwan-based company is establishing a manufacturing center for the U.S. market.
February 11, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Adaptin Bio to Present at the 2026 Sequire Investor Summit in Puerto Rico
January 16, 2026
·
3 min read
Press Releases
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
February 10, 2026
·
6 min read
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
February 24, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
October 30, 2025
·
6 min read
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
February 23, 2026
·
1 min read
·
Annalee Armstrong
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
1 of 38,941
Next
